Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Other Operating Expenses (2022 - 2024)

Denali Therapeutics (DNLI) has disclosed Other Operating Expenses for 2 consecutive years, with $14.5 million as the latest value for Q1 2024.

  • Quarterly Other Operating Expenses changed N/A to $14.5 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2024, changed N/A year-over-year, with the annual reading at $14.5 million for FY2024, N/A changed from the prior year.
  • Other Operating Expenses for Q1 2024 was $14.5 million at Denali Therapeutics, down from $73.3 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $73.3 million in Q4 2022, with the low at $14.5 million in Q1 2024.